Immunotherapy
| Immunotherapy | |
|---|---|
The diagram above represents the process of chimeric antigen receptor T-cell therapy (CAR), this is a method of immunotherapy, which is a growing practice in the treatment of cancer. The final result should be a production of equipped T-cells that can recognize and fight the infected cancer cells in the body.
| |
| MeSH | D007167 |
| OPS-301 code | 8-03 |
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system (https://en.wikipedia.org/wiki/Effector tumor antigen-specific T cells). Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies (Effector tumor antigen-specific T cells) , while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer (https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202409913).
Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells, and cytotoxic T lymphocytes work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells. Vaccine-induced immunity to COVID-19 relies mostly on an immunomodulatory T-cell response.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.